On January 9, 2025, the 2025 Global NGP Compliance Development Symposium, organized by 2Firsts, concluded successfully in Shenzhen. The symposium aimed to promote global compliance development and encourage companies to actively embrace the new era of compliance. Over 10 renowned compliance experts and industry representatives from China and around the world delivered keynote speeches through a combination of online and offline formats, attracting nearly 200 participants from various sectors, including international tobacco companies, leading e-cigarette companies in China, top supply chain companies, and researchers. The conference was organized by the world's leading NGP industry media and consultancy - 2Firsts.
Dr. Charlene Liu, founder of RiskWise Solution, participated in the symposium and delivered an online presentation titled "The Impact of FDA's 2024 APPH Science Policy Memorandum on Compliance Development in the E-cigarette Industry."
Dr. Charlene Liu thoroughly explained the FDA's regulatory requirements for e-cigarette products, the pathway for tobacco products to be marketed in the United States, and the scientific research framework for new tobacco products. She also provided detailed guidance on how companies can ensure their products meet the standards for protecting public health through quantitative risk assessment.
Dr. Charlene Liu also provided key measures for Chinese e-cigarette companies to create high-quality, safe, and compliant e-cigarette products, offering clear guidance for companies looking to enter the American market.
In addition, Dr. Charlene Liu also interacted live with the audience in the United States. The interactive session on this topic was hosted by Dr. Xinan Liu, a researcher at the Brain Institute of the Shenzhen Advanced Institute of the Chinese Academy of Sciences. With guidance from the two scientists, the audience engaged in an in-depth discussion.
Dr. Charlene Liu's professional speech received high recognition and enthusiastic feedback from attendees. After the symposium, attendees provided positive feedback, stating that the information provided valuable guidance for them as they expand into the American market. Attendees also expressed sincere gratitude to the organizers, believing that the event created a high-quality compliance communication platform that greatly facilitated communication and interaction among industry stakeholders, effectively promoting the industry's steady development on the compliance path.
As a leading media and think tank in the field of New Generation Products (NGP) globally, 2Firsts actively maintains close contact with various testing and regulatory agencies, building a solid bridge for industry resource sharing and information exchange. In the future, 2Firsts will continue to integrate resources, gather wisdom, and work with industry partners to jointly promote the high-quality development of the global NGP industry, contributing lasting strength to the industry's innovation breakthroughs and compliance.
Regarding RiskWise Solution
RiskWise Solution is a leading tobacco product toxicology and health risk assessment company based in the United States, specializing in providing comprehensive services for regulatory applications for new tobacco products. We are committed to helping new tobacco products successfully enter the international markets in Europe and America, and have achieved outstanding results in product authorization and applications in the United States.
RiskWise focuses on research related to modules 3 and 4 of the PMTA, covering key services including product design and production compliance, product chemical characteristics and long-term stability research, in vivo and in vitro toxicology testing protocols, and assessment of health and safety risks of novel tobacco products.
RiskWise offers clients a one-stop consulting service for new tobacco products, from concept to market, including e-liquid ingredient analysis, smoking material evaluation, research and development strategy formulation, and regulatory submission. RiskWise prides itself on collaborations with top experts and former FDA CTP officials, who can be involved in specific projects and provide long-term strategic support.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
